Overcoming a Delivery Challenge of Retinal Gene Therapies
Patrick Ritschel, CEO of Atsena Therapeutics, discusses the delivery challenges of gene therapies for inherited retinal diseases, how the company’s unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.